5 Results for "

DARS2

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "DARS2" in MCE Product Catalog:

Cat. No.: HY-RS03533
Research Areas:  

Others

DARS2 Human Pre-designed siRNA Set A contains three designed siRNAs for DARS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS21545
Research Areas:  

Others

Dars2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dars2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS28063
Research Areas:  

Others

Dars2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dars2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
loading...
    loading...
Cat. No.: HY-161901
CAS No.: 1219395-86-4
Target:  

E1/E2/E3 Enzyme

Research Areas:  

Inflammation/Immunology

BC-1293 is an inhibitor for E3 ligase subunit FBXO24. BC-1293 disrupts the interaction between FBXO24 and aspartyl-tRNA synthetase (DARS2) and increases the level of DARS2. BC-1293 increases levels of IL-1β, IL-9, MIP-2, and TNF α, and exhibits immunostimulatory activity in mice .
loading...
    loading...
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Research Areas:  

Cancer

Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer [2].
loading...
    loading...